Hikma’s Half-Year: Steady Progress Amidst Shifting Tides
Hikma Pharmaceuticals has delivered a classic tale of two halves in its H1 2025 results – solid revenue growth offset by margin pressures, yet with enough strategic momentum to confidently reaffirm full-year guidance. Let’s unpack the numbers and nuances.
The Headline Act: Revenue Up, Profits Down
Group revenue climbed 6% to $1.66 billion, a respectable performance driven by volume growth across all key segments and geographies. But the profit picture was more nuanced:
- Core operating profit dipped 7% to $373 million, reflecting product mix shifts, currency headwinds (notably a stronger Euro), and that pesky H1-weighted legal settlement.
- Injectables shone brightest with 12% revenue growth ($683m), though margins softened (30% vs 36.3% in H1 ’24).
- Branded put in a steady 4% revenue increase ($437m), maintaining strong MENA market share.
- Hikma Rx (formerly Generics) saw a slight 1% revenue dip ($523m), expected after a strong H1 ’24, but held its ground in a tough US market.
CEO Riad Mishlawi struck a pragmatic tone: “The strategic changes and renewed focus we put in place have started to deliver tangible results… While core operating profit was lower… we expect a return to growth in the second half.” Translation: Foundations are set, now let’s build.
Strategic Levers Pulled Effectively
Beyond the headline numbers, Hikma made significant strategic strides:
- R&D Firepower: Investment surged 20% YoY, targeting pipeline acceleration – crucial for long-term differentiation.
- Integration On Track: The Xellia acquisition is bedding in well, with its Zagreb R&D centre and product portfolio contributing meaningfully (especially in Injectables).
- Portfolio Wins: Key FDA approvals secured for TYZAVNA™ (vancomycin) and ustekinumab (Stelara® biosimilar), alongside successful MENA launches like palbociclib (Papillio).
- Partnership Power: Seven new deals signed, including an exclusive MENA license for the oncology drug rucaparib with pharmaand GmbH.
Cash, Debt, and the Dividend Sweetener
Operational cash flow landed at $161m (down from $198m in H1 ’24), while net debt increased to $1.32bn (Net Debt/Core EBITDA: 1.7x). This reflects funding for the Xellia deal and brand acquisitions, mitigated by a savvy $500m Eurobond refinancing in July at 5.125% (replacing a 3.25% bond). The Board clearly signalled confidence with a 12% hike in the interim dividend to 36 cents per share – a welcome return for shareholders.
Navigating External Headwinds
Hikma isn’t operating in a vacuum. Two external factors loom:
- US Tariffs: Management is “closely monitoring” potential impacts but states the 2025 outlook already factors in implemented tariffs and related inflation. Their $1bn US manufacturing investment pledge by 2030 is a strategic hedge, reinforcing their position as a major domestic supplier.
- Geopolitical Uncertainty: Conflicts in the Middle East are being managed locally and group-wide to ensure safety and supply chain continuity.
Guidance Reaffirmed: Confidence in H2 Momentum
This is the headline grabber. Despite the H1 profit dip, Hikma stands firm on its 2025 outlook:
- Group Revenue Growth: 4% to 6%
- Core Operating Profit: $730m to $770m
Segment adjustments are telling: Injectables margin guidance is trimmed slightly (32-33% vs “mid-30s”) due to currency and inflation, while Branded revenue growth is nudged up (6-7%). Hikma Rx is expected flat. Crucially, the medium-term vision remains bold: 6-8% revenue CAGR and 7-9% core EBIT CAGR through 2027, targeting $5bn revenue by 2030.
The Takeaway: Steady as She Goes
Hikma’s H1 is a story of disciplined execution amidst external pressures. Revenue growth is broad-based, strategic investments (R&D, Xellia integration, US manufacturing) are on track, and the product pipeline is delivering. The core profit dip, while noted, is framed as temporary – absorbed within the year’s plan. Reaffirming guidance, especially the profit range, signals strong internal confidence in H2 performance drivers and the resilience of their diversified model. The dividend hike is the cherry on top. Investors looking for a pharma player executing a clear, long-term strategy with geographic and segment diversity should find plenty to like here. The second half promises to be the real proof point.
